58.

Calle R, Pilleron JP, Schlienger P, et al. Conservative management of operable breast cancer: ten years’ experience at the Foundation Curie. Cancer 1978;42:2045–2053.

59.

Prosnitz LR, Goldenberg IS, Packard RA, et al. Radiation therapy as initial treatment for early stage cancer of the breast without mastectomy. Cancer 1977;39:917–923.

60.

Harris JR, Helllman S, Silen W. Conservative management of breast cancer. Philadelphia, PA: JB Lippincott, 1983.

61.

Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227–1232.

62.

Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233–1241.

63.

Sarrazin D, Le MG, Arrigada R, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 1989;14:177–184.

64.

Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332:907–911.

65.

van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143–1150.

66.

Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006–2014.

67.

National Institutes of Health. NIH consensus conference on the treatment of early-stage breast cancer. JAMA 1991;265:391–395.

68.

Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66:136–138.

69.

Goffman TE, Laronga C, Wilson L, et al. Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery. Breast J 2004;10:405–411.

70.

Gui GP, Joubert DJ, Reichert R, et al. Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer. Eur J Surg Oncol 2005;31:707– 714.

71.

Changsri C, Prakash S, Sandweiss L, et al. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J 2004;10:392–397.

72.

Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391–401.

73.

Wilson L, Giuliano A. Sentinel lymph node mapping for primary breast cancer. Curr Oncol Rep 2005;7:12–17.

74.

Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335–339.

75.

Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864–1867.

76.

Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;13:2553–2559.

77.

Veronesi U, Viale G, Paganelli G. Sentinel lymph node biopsy in breast cancer: ten year results of a randomized controlled study. Ann Surg 2010;251:595–600.

78.

Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569–575.

79.

Green MC, Hortobagyi GN. Adjuvant chemotherapy for breast cancer. Langenbecks Arch Surg 2002;387:109–116.

80.

Murphy GP, Lawrence W, Lenhard RE, eds. American Cancer Society textbook of clinical oncology. Atlanta, GA: American Cancer Society, 1995:213.

81.

Brezden C, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695–2701.

82.

Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.

83.

Rosen PP, Groshen S, Kinne DW, et al. Factors inﬂuencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090–2100.

84.

Rapiti E, Fioretta G, Verkooigen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer 2005;41:1446–1452.

85.

Trudeau ME, Pritchard KI, Chapman JA, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 2005;89:35–45.

86.

Kollias J, Elston CW, Ellis IO, et al. Early-onset breast cancer— histopathological and prognostic considerations. Br J Cancer 1997;75:1318–1323.

87.

Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with node-positive breast cancer. J Natl Cancer Inst 1998;90:1361–1370.

88.

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783– 792.

89.

Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.

90.

Smith I, Procter M, Gelber RD, et al. HERA study team. 2year follow-up of trastuzumab after adjuvant chemotherapy in

HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.

91.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.

92.

Nissen-Meyer R. The Scandinavian clinical trials. Experientia Suppl 1982;41:571–579.

93.

Bonadonna G, Valagussa P. Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 1985;3:259–275.

94.

Fisher B, Carbone P, Economou SG, et al. L-phenylalanine mustard in the management of primary breast cancer: a report of early findings. N Engl J Med 1975;292:117–122.

95.

Mueller CB, Lesperance ML. NSABP trials of adjuvant chemotherapy for breast cancer: a further look at the evidence. Ann Surg 1991;214:206–211.

96.

Bonadonna G, Rossi A, Valagussa P. Adjuvant CMF chemotherapy in operable breast cancer: ten years later. World J Surg 1985;9:707– 713.

97.

Tancine G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983;1:2–10.

98.

Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10–15.

99.

Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and ﬂuorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901–906.

100.

Zambetti M, Valagussa P, Bonadonna G. Adjuvant CMF in node-negative and estrogen receptor negative breast cancer: updated results. Ann Oncol 1996;7:481–485.

101.

Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and ﬂuorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496.

102.

Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 2003;21:976–983.

103.

Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide:7 year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177– 1183.

104.

Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer 2010;10:196–208.

105.

Trudeau M, Sinclair SE, Clemons M, et al. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systemic review. Cancer Treat Rev 2005;31:283–302.

106.

Chen AM, Meric-Berstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer 2005;103:689–695.

107.

Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930–942.

108.

Albain K, Green S, Ravdin P, et al. Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen is superior to tamoxifen alone in post-menopausal, receptor(+), node(+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100). Proc Am Soc Clin Oncol 2001;20:94(abst).

109.

Fisher B, Digman J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor–positive breast cancer. J Natl Cancer Inst 1997;89:1673–1682.

110.

Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62.

111.

Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509–518.

112.

Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.

113.

Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. In: Devita VT, Hellman S, Rosenberg S, eds. Cancer principles and practice of oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:1651–1717.

114.

Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.

115.

Early Breast Cancer Trialists’ Collaborative Group. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371:29–40.

116.

Dhodapkar MV, Ingle JN, Cha SS, et al. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Cancer 1996;77:683–690.

117.

Valero V. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology 1997;11:34–36.

118.

Burstein HJ, Keshaviah A, Baron AD. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965–972.

119.

Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735–1744.

120.

Pavlakis B, Scmidt RL, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;3:CD003474.

121.

Paget J. Disease of the mammary areola preceding cancer of the mammary gland. St Barts Hosp Rep 1874;10:89.

122.

Pezzi CM, Kukora JS, Audet IM, et al. Breast conservation surgery using nipple-areolar resection for central breast cancers. Arch Surg 2004;139:32–37.

123.

Barnes DM, Newman L. Pregnancy-associated breast cancer: a literature review. Surg Clin North Am 2007;87:417–430.

124.

Simpson PT, Gale T, Fulford LG, et al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res 2003;5:258–262.

125.

Barth A, Brenner RJ, Giuliano AE. Current management of ductal carcinoma in situ. West J Med 1995;163:360–366.

126.

Sneige N, Wang J, Baker BA, et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002;15:1044– 1050.

127.

Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441–452.

128.

Claus EB, Stowe M, Carter D, et al. The risk of contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast 2003;12:451–456.

129.

Psyrri A, Burtness B. Pregnancy-associated breast cancer. Cancer J 2005;11:83–95.

130.

Partridge A, Schapira L. Pregnancy and breast cancer: epidemiology, treatment, and safety issues. Oncology 2005;19:693–697.

131.

Petrek JA. Breast cancer and pregnancy. J Natl Cancer Inst Monogr 1994;16:113–121.

132.

Rosene-Montella K, Larson L. Diagnostic imaging. In: Lee RV, Rosene-Montella K, Barbour A, et al. eds., Medical care of the pregnant patient. Philadelphia, PA: American College of Physicians Press, 2000:103–115.

133.

Bodner-Adler B, Bodner K, Zeisler H. Breast cancer diagnosed during pregnancy. Anticancer Res 2007;27:1705–1707.

134.

Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging 2010;37:78–83.

135.

Gelber S, Coates A, Goldhirsch A, et al. Effect of pregnancy on overall survival after the diagnosis of early stage breast cancer. J Clin Oncol 2001;19:1671–1675.

136.

Mueller BA, Simon MS, Deapen D, et al. Childbearing and survival after breast carcinoma in young women. Cancer 2003;98:1131– 1140.